<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621502</url>
  </required_header>
  <id_info>
    <org_study_id>QUINOA</org_study_id>
    <nct_id>NCT02621502</nct_id>
  </id_info>
  <brief_title>Quinoa Effects on Glycemic Index and Satiety</brief_title>
  <official_title>Pilot Study to Evaluate the Glycemic Index, and the Satiating Effect Using Different Quinoa Varieties in a Group of Healthy Overweight Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alicorp S.A.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to assess the glycemic index and the satiating properties of
      different Quinoa varieties, using a Visual Analogue Scale in a sample of healthy overweight
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot study to evaluate the glycemic index, and the satiating effect using different Quinoa
      varieties in a group of healthy overweight subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic index</measure>
    <time_frame>0, 15, 30, 45, 60, 90, 120 min</time_frame>
    <description>The glycemic index is calculated with the incremental area under the curve of the glycemic response 7 time points ( 0 , 15 , 30, 45 , 60, 90 , 120 min) to 50 g intake carbohydrate food test food and reference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism related parameters</measure>
    <time_frame>day 1, 8, 15, 22, 29</time_frame>
    <description>glucose and insulin assessed in 7 point curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satiety hunger assessment (visual analogue scale)</measure>
    <time_frame>just before taking the product, just after taking the product, 30, 60 , 90, 120, 180, 240 min and 260 min after taking the product)</time_frame>
    <description>visual analogue scale to assessment satiety and hunger will be picked up in 9 time points to calculate the area under the curve to get a score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>day 1, 8, 15, 22, 29</time_frame>
    <description>Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>day 1, 8, 15, 22, 29</time_frame>
    <description>symptoms of gastrointestinal intolerance (nausea, diarrhea, bloating or other gastrointestinal disorder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood hormonal markers</measure>
    <time_frame>just before taking the product, 15, 30, 45, 60, 90 and 120 min after consuming the product</time_frame>
    <description>ghrelin, GLP-1 (glucagon-like peptide) and peptide YY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height</measure>
    <time_frame>day 1, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>day 1, 8, 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>day 1, 8, 15, 22, 29</time_frame>
    <description>body mass index</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Quinoa variety 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinoa variety 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinoa variety 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinoa variety 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anhydrous Glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quinoa variety 1</intervention_name>
    <description>On the intervention day, the volunteers will consume the Quinoa Variety 1.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.</description>
    <arm_group_label>Quinoa variety 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quinoa variety 2</intervention_name>
    <description>On the intervention day, the volunteers will consume the Quinoa Variety 2.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.</description>
    <arm_group_label>Quinoa variety 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quinoa variety 3</intervention_name>
    <description>On the intervention day, the volunteers will consume the Quinoa Variety 3.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.</description>
    <arm_group_label>Quinoa variety 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quinoa variety 4</intervention_name>
    <description>On the intervention day, the volunteers will consume the Quinoa Variety 4.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.</description>
    <arm_group_label>Quinoa variety 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Anhydrous Glucose</intervention_name>
    <description>On the intervention day, the volunteers will consume the control product.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.</description>
    <arm_group_label>Anhydrous Glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women from 18 to 65 years old.

          -  Body mass index (BMI) ≥25 and &lt;30 kg/m2.

          -  Adequate cultural level and understanding for the clinical trial.

          -  Signed informed consent

        Exclusion Criteria:

          -  Individuals with BMI ≥30 or &lt;25 kg/m2

          -  Vegetarians or individuals with a fiber intake ≥30 g/day

          -  Individuals diagnosed with Diabetes Mellitus

          -  Individuals with dyslipidemia on pharmacological treatment

          -  Individuals with hypertension on pharmacological treatment

          -  Smokers or heavy drinking individuals (&gt;2-3 servings/day in men and &gt; 1 serving/day in
             women (1 serving=1 glass of wine or 1 bottle of beer))

          -  Individuals with large weight fluctuations or who have undergone in recent months a
             weight loss diet

          -  Individuals with gastrointestinal diseases that affect the digestion or the absorption
             of nutrients

          -  Individuals receiving at least the preceding 2 months a pharmacological treatment that
             modifies the lipid profile (for example, statins, fibrates, diuretics,
             corticosteroids, oral antidiabetic medications)

          -  Pregnant or breastfeeding women

          -  Women with menstrual irregularities (absence of menstrual cycle at least 2 months
             prior)

          -  Individuals with intense physical activity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gómez Candela, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Paz University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitairo La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.idipaz.es/</url>
    <description>La Paz University Hospital Research Institute</description>
  </link>
  <link>
    <url>http://www.nutrinvest.com</url>
    <description>Research group in Nutrition and Functional Foods (NUTRINVEST)</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quinoa</keyword>
  <keyword>Satiety</keyword>
  <keyword>Visual analogue scale</keyword>
  <keyword>Cross-over studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

